A systematic review of the genetic mechanisms of dolutegravir resistance
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic review of the genetic mechanisms of dolutegravir resistance
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-05-31
DOI
10.1093/jac/dkz256
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients
- (2019) Elżbieta Jabłonowska et al. PLoS One
- Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
- (2019) Michael Aboud et al. LANCET INFECTIOUS DISEASES
- Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle
- (2019) Rachel Van Duyne et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Four class drug resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir based antiretroviral therapy in Botswana
- (2018) Kaelo K. Seatla et al. AIDS
- The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries
- (2018) Marco Vitoria et al. AIDS
- Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir
- (2018) Jennifer A Fulcher et al. CLINICAL INFECTIOUS DISEASES
- Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
- (2018) D Sculier et al. HIV MEDICINE
- Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication
- (2018) A Borghetti et al. HIV MEDICINE
- Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations
- (2018) Erik Sörstedt et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort
- (2018) Charlotte Charpentier et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pathway involving the N155H mutation in HIV-1 integrase leads to dolutegravir resistance
- (2018) Isabelle Malet et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial
- (2018) Jose L Blanco et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)
- (2018) S. Rusconi et al. JOURNAL OF CLINICAL VIROLOGY
- HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy
- (2018) Ingeborg E A Wijting et al. JOURNAL OF INFECTIOUS DISEASES
- Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors
- (2018) Wendy W Zhang et al. JOURNAL OF INFECTIOUS DISEASES
- The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors
- (2018) Hanh T Pham et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
- (2018) Josep M Llibre et al. LANCET
- Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
- (2018) Steven J. Smith et al. Retrovirology
- Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research
- (2018) Jienchi Dorward et al. Lancet HIV
- Rapid Development of High Level Resistance to Dolutegravir with Emergence of T97A Mutation in Two Treatment Experienced Individuals with Baseline Partial Sensitivity to Dolutegravir
- (2018) Jomy M George et al. Open Forum Infectious Diseases
- Two cases of dolutegravir failure with R263K mutation
- (2018) Margarida Cardoso et al. AIDS
- Dolutegravir monotherapy versus dolutegravir/abacavir/lamivudine for virologically suppressed people living with chronic HIV infection: the randomized non-inferiority MONCAY trial
- (2018) Laurent Hocqueloux et al. CLINICAL INFECTIOUS DISEASES
- Non-inferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary HIV infection: a randomized, controlled, multi-site, open-label, non-inferiority trial
- (2018) Dominique L Braun et al. CLINICAL INFECTIOUS DISEASES
- Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA
- (2018) Amesika N Nyaku et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)
- (2018) Véronique Joly et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
- (2018) Pedro Cahn et al. LANCET
- Ultra-long-acting removable drug delivery system for HIV treatment and prevention
- (2018) Martina Kovarova et al. Nature Communications
- Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance
- (2018) N Ahmed et al. Open Forum Infectious Diseases
- Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study
- (2017) P Gantner et al. HIV MEDICINE
- Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital
- (2017) SEJ Todd et al. INTERNATIONAL JOURNAL OF STD & AIDS
- Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice
- (2017) Alonso Heredia et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir monotherapy in HIV-infected naive patients with an HIV-RNA load
- (2017) Massimiliano Lanzafame et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Adult antiretroviral therapy guidelines 2017
- (2017) Graeme Meintjes et al. SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE
- Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors
- (2017) Isabelle Malet et al. mBio
- Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
- (2017) Pedro Cahn et al. Journal of the International AIDS Society
- Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
- (2017) Ingeborg Wijting et al. Lancet HIV
- Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
- (2017) Nicholas I Paton et al. Lancet HIV
- The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir
- (2016) Maureen Oliveira et al. AIDS
- Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results
- (2016) Celia Oldenbuettel et al. ANTIVIRAL THERAPY
- Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients
- (2016) Lisa K Naeger et al. ANTIVIRAL THERAPY
- Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression
- (2016) Jhon Rojas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia
- (2016) C. Katlama et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients: Table 1.
- (2016) Casper Rokx et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors
- (2016) Bluma G. Brenner et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
- (2016) Soo-Yon Rhee et al. JOURNAL OF VIROLOGY
- Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
- (2016) Amedeo F. Capetti et al. PLoS One
- Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients
- (2015) Camelia Gubavu et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance
- (2015) Isabelle Malet et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents
- (2015) Rolando M. Viani et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase
- (2015) Peter K. Quashie et al. JOURNAL OF VIROLOGY
- Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection
- (2014) Tomokazu Yoshinaga et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study
- (2014) Bisher Akil et al. ANTIVIRAL THERAPY
- New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors
- (2014) I. Malet et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance
- (2014) I. Hardy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
- (2014) A. Castagna et al. JOURNAL OF INFECTIOUS DISEASES
- Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
- (2014) Kirsten White et al. Viruses-Basel
- New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
- (2014) Andreas Carganico et al. Journal of the International AIDS Society
- Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase
- (2013) Peter K. Quashie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4
- (2011) Nicolas A. Margot et al. ANTIVIRAL RESEARCH
- The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype
- (2011) I. Malet et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
- (2011) Jose-Luis Blanco et al. JOURNAL OF INFECTIOUS DISEASES
- Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
- (2011) P. K. Quashie et al. JOURNAL OF VIROLOGY
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers
- (2009) S. Min et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now